Organogenesis Holdings Inc. (ORGO)
NASDAQ: ORGO · Real-Time Price · USD
1.790
+0.030 (1.70%)
At close: Aug 14, 2026, 4:00 PM EDT
1.790
0.00 (0.01%)
After-hours: Aug 14, 2026, 7:59 PM EDT
Organogenesis Holdings Revenue
Organogenesis Holdings had revenue of $43.76M in the quarter ending June 30, 2026, a decrease of -56.68%. This brings the company's revenue in the last twelve months to $457.45M, up 6.50% year-over-year. In the year 2025, Organogenesis Holdings had annual revenue of $564.17M with 17.04% growth.
Revenue (ttm)
$457.45M
Revenue Growth
+6.50%
P/S Ratio
0.50
Revenue / Employee
$535,660
Employees
854
Market Cap
230.33M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 564.17M | 82.13M | 17.04% |
| Dec 31, 2024 | 482.04M | 48.90M | 11.29% |
| Dec 31, 2023 | 433.14M | -17.75M | -3.94% |
| Dec 31, 2022 | 450.89M | -16.47M | -3.52% |
| Dec 31, 2021 | 467.36M | 129.06M | 38.15% |
| Dec 31, 2020 | 338.30M | 77.32M | 29.63% |
| Dec 31, 2019 | 260.98M | 67.53M | 34.91% |
| Dec 31, 2018 | 193.45M | -5.06M | -2.55% |
| Dec 31, 2017 | 198.51M | 59.78M | 43.09% |
| Dec 31, 2016 | 138.73M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Emergent BioSolutions | 770.20M |
| Aurora Cannabis | 221.16M |
| Akebia Therapeutics | 219.06M |
| Organigram Global | 217.71M |
| Lifecore Biomedical | 129.46M |
| Anika Therapeutics | 120.65M |
| ADC Therapeutics | 79.58M |
| Journey Medical | 68.18M |
ORGO News
- 7 days ago - Organogenesis price target lowered to $2 from $3 at Truist - TheFly
- 8 days ago - Organogenesis Holdings Earnings Call Transcript: Q2 2026 - Transcripts
- 8 days ago - Organogenesis Holdings Earnings release: Q2 2026 - Filings
- 8 days ago - Organogenesis Holdings Quarterly report: Q2 2026 - Filings
- 8 days ago - Organogenesis Holdings Inc. Reports Second Quarter 2026 Financial Results - GlobeNewsWire
- 18 days ago - Organogenesis Affinity meets primary endpoint in complex venous leg ulcer trial - TheFly
- 18 days ago - Organogenesis Announces Publication of Peer-Reviewed Clinical Trial Results Demonstrating Clinical Benefit of Affinity™ in the Most Challenging and Complex Venous Leg Ulcers - GlobeNewsWire
- 5 weeks ago - Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2026 Financial Results on August 6, 2026 - GlobeNewsWire